These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 19338077)

  • 21. Clonal analysis of TET2 and JAK2 mutations suggests that TET2 can be a late event in the progression of myeloproliferative neoplasms.
    Schaub FX; Looser R; Li S; Hao-Shen H; Lehmann T; Tichelli A; Skoda RC
    Blood; 2010 Mar; 115(10):2003-7. PubMed ID: 20061559
    [TBL] [Abstract][Full Text] [Related]  

  • 22. JAK2 GGCC haplotype in MPL mutated myeloproliferative neoplasms.
    Pietra D; Casetti I; Da Vià MC; Elena C; Milanesi C; Rumi E
    Am J Hematol; 2012 Jul; 87(7):746-7. PubMed ID: 22565617
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Advances in understanding the pathogenesis of familial myeloproliferative neoplasms.
    Rumi E; Cazzola M
    Br J Haematol; 2017 Sep; 178(5):689-698. PubMed ID: 28444727
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Jak2 inhibitors: rationale and role as therapeutic agents in hematologic malignancies.
    Sayyah J; Sayeski PP
    Curr Oncol Rep; 2009 Mar; 11(2):117-24. PubMed ID: 19216843
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Validation of a molecular diagnostic assay for CALR exon 9 indels in myeloproliferative neoplasms: identification of coexisting JAK2 and CALR mutations and a novel 9 bp deletion in CALR.
    Murugesan G; Guenther-Johnson J; Mularo F; Cook JR; Daly TM
    Int J Lab Hematol; 2016 Jun; 38(3):284-97. PubMed ID: 27018326
    [TBL] [Abstract][Full Text] [Related]  

  • 26. JAK2 V617F mutation prevalence in myeloproliferative neoplasms in Pernambuco, Brazil.
    da Silva RR; Domingues Hatzlhofer BL; Machado CG; Lima AS; de Albuquerque DM; dos Santos MN; Fertrin KY; Costa FF; Araújo Ada S; Bezerra MA
    Genet Test Mol Biomarkers; 2012 Jul; 16(7):802-5. PubMed ID: 22304488
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Myeloproliferative neoplasms: from origins to outcomes.
    Nangalia J; Green AR
    Hematology Am Soc Hematol Educ Program; 2017 Dec; 2017(1):470-479. PubMed ID: 29222295
    [TBL] [Abstract][Full Text] [Related]  

  • 28. CYT387, a novel JAK2 inhibitor, induces hematologic responses and normalizes inflammatory cytokines in murine myeloproliferative neoplasms.
    Tyner JW; Bumm TG; Deininger J; Wood L; Aichberger KJ; Loriaux MM; Druker BJ; Burns CJ; Fantino E; Deininger MW
    Blood; 2010 Jun; 115(25):5232-40. PubMed ID: 20385788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. PCM1-JAK2-fusion: a potential treatment target in myelodysplastic-myeloproliferative and other hemato-lymphoid neoplasms.
    Hoeller S; Walz C; Reiter A; Dirnhofer S; Tzankov A
    Expert Opin Ther Targets; 2011 Jan; 15(1):53-62. PubMed ID: 21091042
    [TBL] [Abstract][Full Text] [Related]  

  • 30. JAK/STAT signaling in hematological malignancies.
    Vainchenker W; Constantinescu SN
    Oncogene; 2013 May; 32(21):2601-13. PubMed ID: 22869151
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Essential Thrombocythemia Associated With Germline JAK2 G571S Variant and Somatic CALR Type 1 Mutation.
    Panovska-Stavridis I; Eftimov A; Ivanovski M; Pivkova-Veljanovska A; Cevreska L; Hermouet S; Dimovski AJ
    Clin Lymphoma Myeloma Leuk; 2016 May; 16(5):e55-7. PubMed ID: 27009537
    [No Abstract]   [Full Text] [Related]  

  • 32. TERT rs2736100 A>C SNP and JAK2 46/1 haplotype significantly contribute to the occurrence of JAK2 V617F and CALR mutated myeloproliferative neoplasms - a multicentric study on 529 patients.
    Trifa AP; Bănescu C; Tevet M; Bojan A; Dima D; Urian L; Török-Vistai T; Popov VM; Zdrenghea M; Petrov L; Vasilache A; Murat M; Georgescu D; Popescu M; Pătrinoiu O; Balea M; Costache R; Coleș E; Șaguna C; Berbec N; Vlădăreanu AM; Mihăilă RG; Bumbea H; Cucuianu A; Popp RA
    Br J Haematol; 2016 Jul; 174(2):218-26. PubMed ID: 27061303
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Laboratory practice guidelines for detecting and reporting JAK2 and MPL mutations in myeloproliferative neoplasms: a report of the Association for Molecular Pathology.
    Gong JZ; Cook JR; Greiner TC; Hedvat C; Hill CE; Lim MS; Longtine JA; Sabath D; Wang YL;
    J Mol Diagn; 2013 Nov; 15(6):733-44. PubMed ID: 23978506
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Absence of JAK2V617F mutation in Chinese deep vein thrombosis patients without myeloproliferative neoplasms.
    Dong B; Zhang Y; Fu X; Wang G
    Thromb Res; 2012 May; 129(5):664-5. PubMed ID: 22197451
    [No Abstract]   [Full Text] [Related]  

  • 35. JAK2(V617I) results in cytokine hypersensitivity without causing an overt myeloproliferative disorder in a mouse transduction-transplantation model.
    Brooks SA; Luty SB; Lai HY; Morse SJ; Nguyen TK; Royer LR; Agarwal A; Druker BJ; Fleischman AG
    Exp Hematol; 2016 Jan; 44(1):24-9.e1. PubMed ID: 26458983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. JAK2 46/1 haplotype is associated with JAK2 V617F--positive myeloproliferative neoplasms in Brazilian patients.
    Macedo LC; Santos BC; Pagliarini-e-Silva S; Pagnano KB; Rodrigues C; Quintero FC; Ferreira ME; Baraldi EC; Ambrosio-Albuquerque EP; Sell AM; Visentainer JE
    Int J Lab Hematol; 2015 Oct; 37(5):654-60. PubMed ID: 25959311
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Splanchnic venous thrombosis driven by a constitutively activated JAK2 V617F philadelphia-negative myeloproliferative neoplasm: a case report.
    Waiswa M; Seremba E; Ocama P; Ddungu H; Opio K; Okello C; O'shea T; Verhovsek M; Mutyabule R
    Afr Health Sci; 2014 Dec; 14(4):1069-73. PubMed ID: 25834519
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Next-generation sequencing for JAK2 mutation testing: advantages and pitfalls.
    Maslah N; Verger E; Schlageter MH; Miclea JM; Kiladjian JJ; Giraudier S; Chomienne C; Cassinat B
    Ann Hematol; 2019 Jan; 98(1):111-118. PubMed ID: 30259120
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Determining the role of inflammation in the selection of JAK2 mutant cells in myeloproliferative neoplasms.
    Zhang J; Fleischman AG; Wodarz D; Komarova NL
    J Theor Biol; 2017 Jul; 425():43-52. PubMed ID: 28501635
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications.
    Li SD; Ma M; Li H; Waluszko A; Sidorenko T; Schadt EE; Zhang DY; Chen R; Ye F
    Genome Med; 2017 Oct; 9(1):89. PubMed ID: 29082853
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.